tHEORetically Speaking

HealthEconomics.com
  • 0,0 (0)
  • CIÊNCIAS DA VIDA
  • DUAS VEZES POR SEMANA

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

  1. INsights & OUTcomes with Taylor Hirschberg

    -7 H

    INsights & OUTcomes with Taylor Hirschberg

    This episode features Taylor Hirschberg, an award winning writer, activist, and academic. He is the CEO of Metli Consulting, an inclusive consultancy firm focused on helping to prepare for launch and providing a faster, more flexible approach to market access. Learn more about Metli Consulting: https://www.metliconsulting.com/ “Science without story fails to reach policymakers. Policy without equity fails communities. Story without evidence fails everyone. Metli is a life sciences and public health consulting firm founded at the intersection of science, policy, communications, and human impact.” Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to miss what's next. Join thousands of professionals who trust Health Economics.com as their go to resource. Subscribe for weekly insights, expert commentary, and the latest developments across HEOR and market access: https://healtheconomics.com/subscribe/

    28 min
  2. Weekly News Roundup — Rare Disease Funding Risks, Medicare Advantage Reform, and Global Trade Shifts

    -3 DIAS · BÓNUS

    Weekly News Roundup — Rare Disease Funding Risks, Medicare Advantage Reform, and Global Trade Shifts

    This week’s tHEORetically Speaking News Roundup covers the looming funding crisis for rare disease biotechs as FDA priority review vouchers expire, CMS’s proposed crackdown on Medicare Advantage upcoding, and Cellares’ $257 million raise to scale automated cell therapy manufacturing. We also explore Sanofi’s defense of vaccines amid shifting U.S. policy and a landmark EU–India free trade agreement set to reshape global pharma access.  Tune in for a concise recap of these pivotal industry updates!

    5 min
  3. Weekly News Roundup — Oral GLP-1 Momentum, Trade Tensions, EU Drug Security, and AI Risk Warnings

    23/01 · BÓNUS

    Weekly News Roundup — Oral GLP-1 Momentum, Trade Tensions, EU Drug Security, and AI Risk Warnings

    This week’s tHEORetically Speaking News Roundup covers Novo Nordisk’s early momentum with oral Wegovy amid intensifying GLP-1 competition, rising geopolitical trade tensions threatening pharma market access, and Europe’s push to secure medicine supply chains through the Critical Medicines Act. We also examine new warnings on the misuse of medical AI heading into 2026.  Tune in for this concise recap of the week’s most impactful HEOR, RWE, and market access developments.

    3 min
  4. Weekly News Roundup — Neurodegeneration Deals, Generative AI, and Drug Pricing Politics

    16/01 · BÓNUS

    Weekly News Roundup — Neurodegeneration Deals, Generative AI, and Drug Pricing Politics

    This week’s tHEORetically Speaking News Roundup covers Novartis’ $1.5B Alzheimer’s licensing deal, the FDA’s push to accelerate drug development through Bayesian trial methods, and Bayer’s move to scale generative AI in antibody discovery. We also break down Oxford Biomedica’s takeover talks and a newly unveiled US healthcare cost plan. Tune in for a concise recap of these pivotal industry updates!

    4 min
  5. Weekly News Roundup — Oncology Shakeups, FDA Wellness Crackdown, and AI-Powered Drug Discovery

    12/12/2025 · BÓNUS

    Weekly News Roundup — Oncology Shakeups, FDA Wellness Crackdown, and AI-Powered Drug Discovery

    This week’s tHEORetically Speaking News Roundup covers GSK’s abrupt exit from its five-year synthetic lethality partnership with Ideaya, Whoop’s escalating regulatory clash with the FDA over its unapproved blood-pressure feature, and new evidence showing how minimum wage and EITC policies improve maternal mental health. We also break down Medra’s $52M raise and its new AI-driven drug-discovery partnership with Genentech.  Tune in for this concise recap of these pivotal industry updates!

    3 min
  6. Weekly News Roundup — Tariff-Free Pharma, Biologics Modernization, Duchenne Trial Success, and Maternal Health Advances

    05/12/2025 · BÓNUS

    Weekly News Roundup — Tariff-Free Pharma, Biologics Modernization, Duchenne Trial Success, and Maternal Health Advances

    This week’s tHEORetically Speaking News Roundup breaks down four major developments shaping policy and biopharma. We cover the new US–UK trade deal exempting pharma from tariffs and resetting NHS pricing, the FDA’s push to curb non-human primate testing for monoclonal antibodies, and Capricor’s breakthrough Phase 3 results in Duchenne muscular dystrophy. We also highlight new HEOR research using copula modeling to better understand drivers of low birth weight and preterm birth.  Tune in for a fast, 4-minute briefing on the most important shifts across science, regulation, and market access.

    4 min
  7. Weekly News Roundup — Premium Hikes, Predictive AI Breakthroughs, and Public Health Policy Fallout

    21/11/2025 · BÓNUS

    Weekly News Roundup — Premium Hikes, Predictive AI Breakthroughs, and Public Health Policy Fallout

    This week’s tHEORetically Speaking News Roundup covers Medicare’s 10% Part B premium hike for 2026 and its potential to push more seniors toward Medicare Advantage, Clairity’s $43M raise to expand its FDA-cleared predictive AI platform beyond mammography, and the RISE Committee’s controversial move to exclude public health degrees from its professional program definition. Tune in for this concise recap of these pivotal policy, innovation, and workforce updates!

    4 min
  8. Weekly News Roundup — Four Big Moves in Medtech, Neurotech, Biopharma R&D & Pharma M&A

    14/11/2025 · BÓNUS

    Weekly News Roundup — Four Big Moves in Medtech, Neurotech, Biopharma R&D & Pharma M&A

    This week on tHEORetically Speaking, we’re covering four major stories shaping the landscape across medtech, neurotech, drug development, and global pharma: Laborie buys Organon’s Jada system, NextSense raises a new round to launch EEG Smartbuds, Evotec and BMS hit an IND milestone, and Merck goes big with a $9.2B antiviral acquisition.  A fast, focused roundup of the headlines you need to know. Subscribe for weekly drops!

    3 min
Ver tudo (73)

Sobre

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

Informação

  • Autoria
    HealthEconomics.com
  • Anos em atividade
    2022 - 2026
  • Episódios
    73
  • Classificação
    Explícito
  • Copyright
    © 2026 tHEORetically Speaking
  • Site do programa
    tHEORetically Speaking